REPL Stock Skyrockets Over 100% as FDA Accepts Key Resubmission for Game-Changing Melanoma Therapy
Folks, buckle up because the market’s throwing a curveball that’s got biotech investors buzzing like never before. As of this writing, early in the trading session on October 20, 2025, shares of Replimune Group Inc. (NASDAQ: REPL) are up a jaw-dropping 108%—that’s right, more than doubling from Friday’s close, hovering around $9.37. If you’re glued … Read more